Latest Boehringer Ingelheim Stories
LAUSANNE, Switzerland and HAMBURG, Germany, April 2, 2014 /PRNewswire/ -- - Innovative partnership based on Evotec's Target X projects
CAMBRIDGE, England, March 31, 2014 /PRNewswire/ -- Convergence Pharmaceuticals Holdings Limited ("Convergence"), the company focused on the development of novel and high
Cardiologists also believe their patients' top concern is the fear of experiencing a clot that leads to a stroke; real-world challenges may influence treatment decisions RIDGEFIELD, Conn.,
DUBLIN, March 25, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/skgh5l/investigation) has announced the addition of the "Investigation
Presentations to include research around antidote for dabigatran, a post-hoc analysis of data from the RE-LY® trial and data from the GLORIA(TM)-AF registry RIDGEFIELD, Conn., March 24, 2014
A new lawsuit was filed on March 19, by a widow in Pennsylvania Eastern District Court alleging that her husband died from renal failure and intracerebral hemorrhage caused by Pradaxa.
Positive opinion is based on data from one of the largest clinical registration programs in its class, involving more than 13,000 adults with type 2 diabetes RIDGEFIELD, Conn.
Pharmica Consulting, the industry leader in life science processes and technology, is pleased to announce that John Olszewski of Boehringer Ingelheim USA will speak at Pharmica’s SharePoint
According to a Court Order filed in March 13, new sanctions were imposed on Boehringer Ingelheim for Pradaxa Multidistrict Litigation discovery abuses.
- totally perplexed and mixed up.